Title

Inhaled aztreonam

UMMS Affiliation

Department of Pediatrics

Date

5-1-2010

Document Type

Article

Medical Subject Headings

Administration, Inhalation; Anti-Bacterial Agents; use; Aztreonam; Cystic Fibrosis; Drug Discovery; Humans; Lysine; Pseudomonas Infections; Pseudomonas aeruginosa; Treatment Outcome

Disciplines

Allergy and Immunology | Pediatrics | Respiratory Tract Diseases

Abstract

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.

Rights and Permissions

Citation: Nat Rev Drug Discov. 2010 May;9(5):357-8. Link to article on publisher's site

Related Resources

Link to Article in PubMed

PubMed ID

20431562